Solid forms of an ask1 inhibitor

Abstract

Also provided are processes of manufacture and methods of using the crystalline forms.

1 .- 91 . (canceled) 
     
     
         92 . Crystalline 5-(4-cyclopropyl-1H-imidazol-1-yl)-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide adipate (Compound I Adipate Form I) characterized by an X-ray powder diffractogram comprising the following peaks: 6.4, 14.6, and 24.5° 2θ±0.2° 2θ, as determined on a diffractometer using Cu—Kα radiation at a wavelength of 1.5406 Å. 
     
     
         93 . Compound I Adipate Form I according to  claim 92 , wherein the diffractogram comprises additional peaks at 9.7, 12.1, and 19.3° 2θ±0.2° 2θ. 
     
     
         94 . Compound I Adipate Form I according to  claim 92 , wherein the diffractogram is substantially shown in  FIG. 51 . 
     
     
         95 . Compound I Adipate Form I according to  claim 92 , characterized by a differential scanning calorimetry (DSC) curve that comprises an endotherm at about 151° C. 
     
     
         96 . Compound I Adipate Form I according to  claim 92 , wherein the DSC curve is substantially shown in  FIG. 52 . 
     
     
         97 . A pharmaceutical composition comprising Compound I Adipate Form I according to  claim 92  and one or more pharmaceutically acceptable carriers. 
     
     
         98 . A method of treating a disease mediated, at least in part, by ASK1 in a patient in need thereof comprising administering a therapeutically effective amount of Compound I Adipate Form I according to  claim 92 . 
     
     
         99 . The method of  claim 98 , wherein the disease is diabetes, diabetic nephropathy, kidney disease, kidney fibrosis, lung fibrosis, idiopathic pulmonary fibrosis (IPF), liver fibrosis, pulmonary hypertension, non-alcoholic steatohepatitis, liver disease, alcoholic liver disease, alcoholic hepatitis, an inflammatory condition, an autoimmune disease, a proliferative disease, a transplantation rejection, a disease involving impairment of cartilage turnover, a congenital cartilage malformation, or a disease associated with hypersecretion of IL6. 
     
     
         100 . The method of  claim 98 , further comprising administering another therapeutic agent. 
     
     
         101 . The method of  claim 100 , wherein the another therapeutic agent is filgotinib. 
     
     
         102 . The method of  claim 100 , wherein the another therapeutic agent is a compound of formula: 
       
         
           
           
               
               
           
         
       
       or a salt thereof. 
     
     
         103 . The method of  claim 98 , wherein the disease is an inflammatory condition. 
     
     
         104 . The method of  claim 98 , wherein the disease is Crohn's disease. 
     
     
         105 . The method of  claim 98 , wherein the disease is rheumatoid arthritis. 
     
     
         106 . The method of  claim 98 , wherein the disease is inflammatory bowel disease. 
     
     
         107 . The method of  claim 98 , wherein the disease is non-alcoholic steatohepatitis. 
     
     
         108 . The method of  claim 98 , wherein the disease is alcoholic hepatitis.